Himanshu Upadhyaya1, Christopher Kratochvil2, Jaswinder Ghuman3, Angelo Camporeale4, Sarah Lipsius5, Deborah D'Souza5, Yoko Tanaka1. 1. 1 Lilly Research Laboratories , Eli Lilly and Company, Indianapolis, Indiana. 2. 2 Clinical Research, Department of Psychiatry, University of Nebraska Medical Center , Omaha, Nebraska. 3. 3 Child and Adolescent Psychiatry, The University of Arizona , Tucson, Arizona. 4. 4 Eli Lilly Italia S.p.A. , Sesto Fiorentino, Firenze, Italy . 5. 5 inVentiv Health Clinical , Blue Bell, Pennsylvania.
Abstract
OBJECTIVES: This extrapolation analysis qualitatively compared the efficacy and safety profile of atomoxetine from Lilly clinical trial data in 6-7-year-old patients with attention-deficit/hyperactivity disorder (ADHD) with that of published literature in 4-5-year-old patients with ADHD (two open-label [4-5-year-old patients] and one placebo-controlled study [5-year-old patients]). METHODS: The main efficacy analyses included placebo-controlled Lilly data and the placebo-controlled external study (5-year-old patients) data. The primary efficacy variables used in these studies were the ADHD Rating Scale-IV Parent Version, Investigator Administered (ADHD-RS-IV-Parent:Inv) total score, or the Swanson, Nolan and Pelham (SNAP-IV) scale score. Safety analyses included treatment-emergent adverse events (TEAEs) and vital signs. Descriptive statistics (means, percentages) are presented. RESULTS:Acute atomoxetine treatment improved core ADHD symptoms in both 6-7-year-old patients (n=565) and 5-year-old patients (n=37) (treatment effect: -10.16 and -7.42). In an analysis of placebo-controlled groups, the mean duration of exposure to atomoxetine was ∼ 7 weeks for 6-7-year-old patients and 9 weeks for 5-year-old patients. Decreased appetite was the most common TEAE in atomoxetine-treated patients. The TEAEs observed at a higher rate in 5-year-old versus 6-7-year-old patients were irritability (36.8% vs. 3.6%) and other mood-related events (6.9% each vs. <3.0%). Blood pressure and pulse increased in both 4-5-year-old patients and 6-7-year-old patients, whereas a weight increase was seen only in the 6-7-year-old patients. CONCLUSIONS: Although limited by the small sample size of the external studies, these analyses suggest that in 5-year-old patients with ADHD, atomoxetine may improve ADHD symptoms, but possibly to a lesser extent than in older children, with some adverse events occurring at a higher rate in 5-year-old patients.
RCT Entities:
OBJECTIVES: This extrapolation analysis qualitatively compared the efficacy and safety profile of atomoxetine from Lilly clinical trial data in 6-7-year-old patients with attention-deficit/hyperactivity disorder (ADHD) with that of published literature in 4-5-year-old patients with ADHD (two open-label [4-5-year-old patients] and one placebo-controlled study [5-year-old patients]). METHODS: The main efficacy analyses included placebo-controlled Lilly data and the placebo-controlled external study (5-year-old patients) data. The primary efficacy variables used in these studies were the ADHD Rating Scale-IV Parent Version, Investigator Administered (ADHD-RS-IV-Parent:Inv) total score, or the Swanson, Nolan and Pelham (SNAP-IV) scale score. Safety analyses included treatment-emergent adverse events (TEAEs) and vital signs. Descriptive statistics (means, percentages) are presented. RESULTS: Acute atomoxetine treatment improved core ADHD symptoms in both 6-7-year-old patients (n=565) and 5-year-old patients (n=37) (treatment effect: -10.16 and -7.42). In an analysis of placebo-controlled groups, the mean duration of exposure to atomoxetine was ∼ 7 weeks for 6-7-year-old patients and 9 weeks for 5-year-old patients. Decreased appetite was the most common TEAE in atomoxetine-treated patients. The TEAEs observed at a higher rate in 5-year-old versus 6-7-year-old patients were irritability (36.8% vs. 3.6%) and other mood-related events (6.9% each vs. <3.0%). Blood pressure and pulse increased in both 4-5-year-old patients and 6-7-year-old patients, whereas a weight increase was seen only in the 6-7-year-old patients. CONCLUSIONS: Although limited by the small sample size of the external studies, these analyses suggest that in 5-year-old patients with ADHD, atomoxetine may improve ADHD symptoms, but possibly to a lesser extent than in older children, with some adverse events occurring at a higher rate in 5-year-old patients.
Authors: Lenard Adler; Anthony Dietrich; Fred W Reimherr; Leslie V M Taylor; Virginia K Sutton; Rosalie Bakken; Albert J Allen; Douglas Kelsey Journal: Ann Clin Psychiatry Date: 2006 Apr-Jun Impact factor: 1.567
Authors: Mary Margaret Gleason; Helen Link Egger; Graham J Emslie; Laurence L Greenhill; Robert A Kowatch; Alicia F Lieberman; Joan L Luby; Judith Owens; Lawrence D Scahill; Michael S Scheeringa; Brian Stafford; Brian Wise; Charles H Zeanah Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-12 Impact factor: 8.829
Authors: Laurence Greenhill; Scott Kollins; Howard Abikoff; James McCracken; Mark Riddle; James Swanson; James McGough; Sharon Wigal; Tim Wigal; Benedetto Vitiello; Anne Skrobala; Kelly Posner; Jaswinder Ghuman; Charles Cunningham; Mark Davies; Shirley Chuang; Tom Cooper Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-11 Impact factor: 8.829
Authors: Christopher J Kratochvil; Laurence L Greenhill; John S March; William J Burke; Brigette S Vaughan Journal: CNS Drugs Date: 2004 Impact factor: 5.749
Authors: Craig Donnelly; Mark Bangs; Paula Trzepacz; Ling Jin; Shuyu Zhang; Michael M Witte; Susan G Ball; Thomas J Spencer Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-02 Impact factor: 8.829
Authors: Shannon G Panther; Alice M Knotts; Tamara Odom-Maryon; Kenneth Daratha; Teri Woo; Tracy A Klein Journal: J Pediatr Pharmacol Ther Date: 2017 Nov-Dec